What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends!
--------
24:33
E119: Teclistamab for Rheumatology Writ Large
One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wanted to share what I think may be the ultimate destination for "more B cell depletion than rituximab" strategies.
Article: https://www.nejm.org/doi/full/10.1056/NEJMc2407150
--------
10:52
E118: The emerging risk of overdiagnosis in RA and PMR
Podcast this week about overdiagnosis! Currently one of my favorite topics and something that I think will be an emerging issue in our field. We recently published a Viewpoint in Lancet Rheumatology (https://pubmed.ncbi.nlm.nih.gov/39341221/) addressing this issue. I'm going to read from it and after that will be giving a few final (spicy) thoughts on the topic. Hope you find it worthwhile! s
--------
16:02
E117: Inebilizumab for IgG4-RD (MITIGATE)
New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone!
--------
12:55
E116: A New Paradigm for PMR
Reading one of my recent newsletters this week, this one about PMR tapers. Be sure to subscribe at ebrheum.com if you want access to the visuals and upcoming editions!
Listen to The Evidence Based Rheumatology Podcast, Feel Better, Live More with Dr Rangan Chatterjee and many other podcasts from around the world with the radio.net app
![Podcast Kim Hill Wants To Know](https://nz.radio.net/podcast-images/300/kim-hill-wants-to-know.jpeg?version="c097231ba1e13867880e6fd93fea8717")
New Zealand